Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2015	Nov. 02, 2015
Document And Entity Information
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	0000025743
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		177,848,041
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 81,123,988	$ 51,361,607
Accounts receivable, net of allowance for doubtful accounts of $96,916 and $59,753, respectively	3,666,586	2,154,217
Inventory	870,059	1,182,113
Other current assets	2,120,805	1,537,407
Total current assets	87,781,438	56,235,344
Fixed assets, net	56,748	63,293
Other Assets:
Prepaid expense	1,172,051	1,427,263
Intangible assets, net	1,324,284	1,228,588
Security deposit	125,000	125,000
Total other assets	2,621,335	2,780,851
Total assets	90,459,521	59,079,488
Current Liabilities:
Accounts payable	5,301,625	6,327,129
Other current liabilities	6,386,777	3,840,639
Deferred revenue		522,613
Total current liabilities	11,688,402	10,690,381
Long-Term Liabilities:
Accrued Expense	1,213,874
Total liabilities	12,902,276	10,690,381
Stockholders' Equity:
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 350,000,000 and 250,000,000 shares authorized; 177,787,927 and 156,097,019 issued and outstanding, respectively	177,788	156,097
Additional paid in capital	279,723,640	182,982,846
Accumulated deficit	(202,344,183)	(134,749,836)
Total stockholders' equity	77,557,245	48,389,107
Total liabilities and stockholders' equity	$ 90,459,521	$ 59,079,488

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 96,916	$ 59,753
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	250,000,000
Common stock, shares issued	177,787,927	156,097,019
Common stock, shares outstanding	177,787,927	156,097,019

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenues, net	$ 5,190,175	$ 4,186,261	$ 14,513,158	$ 10,768,572
Cost of goods sold	1,193,965	1,068,605	3,270,695	2,792,268
Gross profit	3,996,210	3,117,656	11,242,463	7,976,304
Operating expenses:
Sales, general, and administrative	7,060,944	6,043,354	20,089,998	16,610,015
Research and development	16,421,753	14,909,430	58,789,302	29,052,149
Depreciation and amortization	16,548	12,747	44,400	39,909
Total operating expense	23,499,245	20,965,531	78,923,700	45,702,073
Operating loss	(19,503,035)	(17,847,875)	(67,681,237)	(37,725,769)
Other income (expense):
Miscellaneous income	27,630	6,260	71,728	43,411
Interest income	2,760	9,364	15,162	27,756
Financing costs				(260,027)
Total other income (expense)	30,390	15,624	86,890	(188,860)
Loss before income taxes	(19,472,645)	(17,832,251)	(67,594,347)	(37,914,629)
Net loss	$ (19,472,645)	$ (17,832,251)	$ (67,594,347)	$ (37,914,629)
Loss per share, basic and diluted:
Net loss per share, basic and diluted	$ (0.11)	$ (0.12)	$ (0.39)	$ (0.26)
Weighted average number of common shares outstanding, basic and diluted	177,206,168	152,200,455	171,589,595	147,594,810

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (67,594,347)	$ (37,914,629)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	22,104	22,713
Amortization of intangible assets	22,296	17,196
Provision for doubtful accounts	37,163	2,594
Stock based compensation	4,740,906	3,934,836
Amortization of deferred financing costs		260,027
Changes in operating assets and liabilities:
Accounts receivable	(1,549,532)	(460,565)
Inventory	312,054	31,673
Other current assets	(621,923)	197,569
Other assets	(15,162)	(17,069)
Accounts payable	(1,025,504)	3,534,462
Deferred revenue	(522,613)	(754,431)
Other current liabilities	2,546,138	909,890
Long term accrued expenses	1,213,874
Net cash flows used in operating activities	(62,434,546)	(30,235,734)
CASH FLOWS FROM INVESTING ACTIVITIES
Patent costs	(117,992)	(193,349)
Purchase of property and equipment	(15,559)	(30,962)
Net cash flows used in investing activities	(133,551)	(224,311)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock, net of costs	91,374,649	42,771,353
Proceeds from exercise of options	589,829	315,546
Proceeds from exercise of warrants	366,000	181,000
Net cash flows provided by financing activities	92,330,478	43,267,899
Increase in cash	29,762,381	12,807,854
Cash, beginning of period	51,361,607	54,191,260
Cash, end of period	$ 81,123,988	$ 66,999,114

THE COMPANY

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

THE COMPANY

NOTE 1 – THE COMPANY

TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed, BocaGreenMD, Inc., a Nevada corporation, or BocaGreen, and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as "our company," "we," "our," or "us."

Nature of Business

We are a women’s health care product company focused on creating and commercializing products targeted exclusively for women. As of the date of these unaudited consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References+ Details

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

NOTE 2 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Interim Financial Statements

The accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated balance sheet as of December 31, 2014. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year, or any other interim period.

Recently Issued Accounting Pronouncements

In July 2015, the Financial Accounting Standards Board, or FASB, issued final guidance that requires entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of “market.” The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.

In June 2015, the FASB issued Accounting Standards Update, or ASU, No. 2015-10, Technical Corrections and Improvements, to correct differences between original guidance and the Accounting Standards Codification, or ASC, clarify the guidance, correct references and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The other amendments are effective immediately. We do not expect the adoption of ASU 2015-10 to have a material effect on our consolidated financial statements and disclosures.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.

In May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements and disclosures.

We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Impairment of Long-Lived Assets

We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. There was no impairment of any long-lived assets during the three and nine months ended September 30, 2015 and 2014.

Fair Value of Financial Instruments

Our financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments.

We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, Fair Value Measurements. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:

	Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
	Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
	Level 3	unobservable inputs for the asset or liability.

At September 30, 2015 and December 31, 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.

The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test.

Revenue Recognition

We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.

Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques.

Over-the-Counter Products

We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.

Prescription Products

We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.

We accept returns of unsalable product from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on certain arrangements until the right of return no longer existed.

We maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.

Research and Development Expenses

Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities were $948,499 at September 30, 2015, of which $755,152 was included in Other current assets and $193,347 was included in long term Prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future research and development activities were $1,175,082 at December 31, 2014, of which $711,362 was included in Other current assets and $463,720 was included in long term Prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as research and development expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding research and development, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. As of September 30, 2015, we classified $1,213,874 of the accrued clinical study costs as long term Accrued Expenses related to the costs that will be paid at the completion of one of our clinical trials. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.

Segment Reporting

We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

INVENTORY

9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

INVENTORY

NOTE 4 – INVENTORY

Inventory consists of the following:

	September 30, 2015		December 31, 2014
Finished product	$	787,232	$	874,294
Raw material		82,827		155,341
Deferred costs		—		152,478
TOTAL INVENTORY	$	870,059	$	1,182,113

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

FIXED ASSETS, NET

9 Months Ended

Sep. 30, 2015

Property, Plant and Equipment [Abstract]

FIXED ASSETS

NOTE 6 – FIXED ASSETS, NET

Fixed assets, net consist of the following:

	September 30, 2015			December 31, 2014
Equipment	$	132,150		$	132,150
Furniture and fixtures		69,454			53,895
		201,604			186,045
Accumulated depreciation		(144,856	)		(122,752	)
TOTAL FIXED ASSETS, NET	$	56,748		$	63,293

Depreciation expense for the three months ended September 30, 2015 and 2014 was $7,856 and $7,122, respectively, and $22,104 and $22,713 for the nine months ended September 30, 2015 and 2014, respectively.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 8 – INTANGIBLE ASSETS, NET

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2015 and December 31, 2014:

	September 30, 2015
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:
OPERA^®software patent	$	31,951	$	(3,994	)	$	27,957		14
Development costs of
corporate website		91,743		(91,743	)		—		n/a
Approved hormone
therapy drug
candidate patents		605,502		(40,199	)		565,303		17.25
Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents
(pending)		585,241		—			585,241		n/a
Multiple trademarks for
vitamins/supplements		145,783		—			145,783		indefinite
Total	$	1,460,220	$	(135,936	)	$	1,324,284

	December 31, 2014
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:
OPERA^®software patent	$	31,951	$	(2,496	)	$	29,455		14.75
Development costs of
corporate website		91,743		(91,743	)		—		n/a
Approved hormone
therapy drug
candidate patents		439,184		(19,401	)		419,783		18
Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents
(pending)		675,982		—			675,982		n/a
Multiple trademarks for
vitamins/supplements		103,368		—			103,368		indefinite
Total	$	1,342,228	$	(113,640	)	$	1,228,588

We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time.

Trademarks are perpetual and are not amortized. As of September 30, 2015, the remaining life related to OPERA® patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately 17 years. During the three and nine months ended September 30, 2015 and 2014, there was no impairment recognized.

In addition to numerous pending patent applications, as of September 30, 2015, we had 13 issued patents, including:

	·	one method patent that relates to our OPERA® information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029;
	·	twelve utility patents that relate to our combination progesterone and estradiol formulations, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Canada, the European Union, Israel, Mexico, Brazil, Japan, Russia, South Africa and South Korea.

Amortization expense was $8,692 and $5,625 for the three months ended September 30, 2015 and 2014, respectively and $22,296 and $17,196 for the nine months ended September 30, 2015 and 2014, respectively. Estimated amortization expense for the next five years is as follows:

Year Ending December 31,		Estimated Amortization
	2015 (3 months)	$	8,692
	2016	$	34,768
	2017	$	34,768
	2018	$	34,768
	2019	$	34,768

OTHER CURRENT LIABILITIES

9 Months Ended

Sep. 30, 2015

Other Liabilities Disclosure [Abstract]

OTHER CURRENT LIABILITIES

NOTE 9 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	September 30, 2015		December 31, 2014
Accrued clinical trial costs	$	3,528,061	$	1,706,542
Accrued payroll, bonuses and commission costs		930,913		814,205
Accrued legal and accounting expense		615,946		276,470
Accrued compensated absences		490,170		442,430
Other accrued expenses		388,268		185,965
Allowance for coupons and returns		208,361		90,446
Allowance for wholesale distributor fees		96,440		160,503
Accrued rent		86,998		91,368
Accrued royalties		41,620		72,710
TOTAL OTHER CURRENT LIABILITIES	$	6,386,777	$	3,840,639

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2015

Net Loss Per Share

NET LOSS PER SHARE

NOTE 10 – NET LOSS PER SHARE

We calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of our Common Stock outstanding subject to repurchase or forfeiture for the three and nine months ended September 30, 2015 and 2014.

Since we are in a net loss position, we have excluded outstanding stock options, all of which are subject to forfeiture, as well as warrants for the purchase of our Common Stock from our calculation of diluted net loss per share.

The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.

	As of September 30,
	2015		2014
Stock options		17,414,242		16,851,943
Warrants		12,722,431		13,927,916
		30,136,673		30,779,859

- Definition

The entire disclosure for earnings per share.

+ References+ Details

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2015

Stockholders' Equity:

STOCKHOLDERS' EQUITY

NOTE 11 – STOCKHOLDERS’ EQUITY

Preferred Stock

At September 30, 2015, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred Stock were issued or outstanding.

Common Stock

At September 30, 2015, we had 350,000,000 shares of Common Stock authorized, of which 177,787,927 shares of Common Stock were issued and outstanding.

On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July 15, 2015 and we issued 4,423,077 shares of our Common Stock.

On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.

On July 29, 2014, we entered into an underwriting agreement with Goldman Sachs & Co, or Goldman Sachs, as the representative of the underwriters named therein, or the Goldman Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of Common Stock. The price to the public in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a 30-day option to purchase up to an additional 1,284,796 shares of Common Stock. On July 30, 2014, the Goldman Sachs Underwriters exercised their option to purchase the additional 1,284,796 shares of Common Stock. Net proceeds from this offering were approximately $42.8 million, after deducting underwriting discounts and commissions and other offering expenses. The offering closed on August 4, 2014 and we issued 9,850,106 shares of our Common Stock.

Exercises During 2015

During the three months ended September 30, 2015, certain individuals exercised stock options to purchase 95,000 shares of Common Stock for $98,478 in cash. During the nine months ended September 30, 2015, certain individuals exercised stock options to purchase 472,867 shares of Common Stock for $589,829 in cash.

Exercises During 2014

During the nine months ended September 30, 2014, certain individuals exercised stock options to purchase 793,800 shares of Common Stock. Stock options to purchase shares of Common Stock were exercised as follows: (i) 674,193 options for $315,546 in cash and (ii) 119,607 options, pursuant to the stock options’ cashless provision, wherein 113,837 shares of Common Stock were issued. Also during the nine months ended September 30, 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were granted in December 2013.

Warrants to Purchase Common Stock

As of September 30, 2015, we had warrants outstanding to purchase an aggregate of 12,772,431 shares of Common Stock with a weighted-average contractual remaining life of 1.92 years, and exercise prices ranging from $0.24 to $6.35 per share, resulting in a weighted average exercise price of $1.93 per share.

The valuation methodology used to determine the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.

In January 2013, we granted warrants to purchase 1,250,000 shares of Common Stock in connection with the issuance of a Revolving Credit Note to Plato and Associates, LLC, or the Plato Warrant. The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. For the nine months ended September 30, 2015 and 2014, $0 and $260,027, respectively, was recorded as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.

In May 2013, we entered into a consulting agreement with Sancilio & Company, Inc., or SCI, to develop drug technology to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:

283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;

283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. As of September 30, 2015, we recorded $115,543 in other current assets in the accompanying consolidated financial statements with respect to such shares. During the three and nine month periods ended September 30, 2015 and 2014, we recorded $38,517 and $115,551, respectively, as non-cash compensation in the accompanying consolidated financial statements with respect to such shares; and

283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will not occur before December 2016.

As of September 30, 2015, unamortized costs associated with the SCI warrants issued in 2013 and 2012 totaled approximately $567,000 and will be recognized over a period of 1.75 years.

During the nine months ended September 30, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant at an exercise price of $6.35 and the expiration date of April 6, 2020. The total non-cash compensation expense related to this warrant was $42,266 and $86,008, respectively, for the three and nine months ended September 30, 2015.

Warrant exercises

During the three months ended September 30, 2015, certain individuals and an entity exercised warrants to purchase 310,000 shares of Common Stock pursuant to the warrants’ cashless exercise provisions, wherein 232,197 shares of Common Stock were issued. During the nine months ended September 30, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000 shares of Common Stock were exercised pursuant to the warrants’ cashless exercise provisions, wherein 232,197 shares of Common Stock were issued.

During the nine months ended September 30, 2014, certain individuals exercised warrants to purchase 365,583 shares of Common Stock for $181,000 in cash.

Options to Purchase Common Stock

In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. During the nine months ended September 30, 2015, we granted 1,231,000 non-qualified stock options under the 2009 Plan. As of September 30, 2015, there were non-qualified stock options to purchase 15,445,768 shares of Common Stock outstanding under the 2009 Plan.

In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of September 30, 2015, there were non-qualified stock options to purchase 1,968,474 shares of Common Stock outstanding under the 2012 Plan.

The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including estimated volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the nine months ended September 30, 2015 and 2014 are set forth in the table below.

	Nine Months Ended September 30,
	2015			2014
Risk-free interest rate		1.47-1.54	%		1.68-1.77	%
Volatility		58.77-62.94	%		69.15-70.93	%
Term (in years)		5.27-6.25			5-6.25
Dividend yield		0.00	%		0.00	%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual terms of the stock option using the simplified method.

A summary of activity under the 2009 and 2012 Plans and related information follows:

	Number of Shares Underlying Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2014		16,792,443		$	1.88		6.92	$	43,996,311
Granted		1,231,000		$	6.38
Exercised		(472,867	)	$	1.25
Expired/Forfeited		(136,334	)	$	3.01
Balance at September 30, 2015		17,414,242		$	2.21		6.09	$	64,265,785
Vested and Exercisable at September 30, 2015		13,848,923		$	1.59		5.49	$	59,095,453

At September 30, 2015, our outstanding stock options had exercise prices ranging from $0.10 to $7.72 per share.

Share-based compensation expense for options recognized in our results of operations (based on vested awards) for the three and nine months ended September 30, 2015 were $1,626,862 and $4,328,964, respectively, and $1,047,493 and $3,341,604, respectively, for the same periods in 2014. ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. At September 30, 2015, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $5,593,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 2.3 years. No tax benefit was realized due to a continued pattern of operating losses.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

+ Details

INCOME TAXES

9 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 12 – INCOME TAXES

Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2015 as a result of (i) the losses recorded during the nine months ended September 30, 2015, (ii) additional losses expected for the remainder of 2015, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is "more likely than not" that some component or all of the benefits of deferred tax assets will not be realized. As of September 30, 2015, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

RELATED PARTIES

9 Months Ended

Sep. 30, 2015

RELATED PARTIES

NOTE 13 – RELATED PARTIES

On February 29, 2012, Cooper C. Collins, who was then president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed by independent directors of our company or a committee consisting of independent directors of our company.

During the nine months ended September 30, 2015 and 2014, we did not engage in any transactions with Pernix. At September 30, 2015 and December 31, 2014, there were amounts due Pernix of approximately $46,000.

Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter stemming from a license and supply agreement in the amounts of approximately $250,000 at both September 30, 2015 and December 31, 2014.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

BUSINESS CONCENTRATIONS

9 Months Ended

Sep. 30, 2015

Risks and Uncertainties [Abstract]

BUSINESS CONCENTRATIONS

NOTE 14 - BUSINESS CONCENTRATIONS

We purchase our products from several suppliers with approximately 54% and 77% of our purchases supplied from one vendor for the nine months ended September 30, 2015 and 2014, respectively.

We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from four major customers accounted for approximately 90% and 95% of our recognized revenue for the nine months ended September 30, 2015 and 2014, respectively.

Customers that generated more than 10% of our sales are designated as customers “A”, “B”, “C” and “D”.

During the nine months ended September 30, 2015, two customers generated more than 10% of revenues and during the nine months ended September 30, 2014, four customers generated more than 10% of revenues. During the nine months ended September 30, 2015, customer A generated approximately $6,930,000 in revenues and customer B generated approximately $3,005,000 in revenues. During the nine months ended September 30, 2014, customers A, B, C and D generated approximately $3,930,000, $1,846,000, $1,590,000 and $1,555,000 in sales, respectively.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 15 – COMMITMENTS AND CONTINGENCIES

We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30, 2018. On February 18, 2015, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant to an addendum to such lease. This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.

The straight line rental expense related to our current lease totaled approximately $119,000 and $90,000 for the three months ended September 30, 2015 and 2014, respectively, and approximately $328,000 and $271,000 for the nine months ended September 30, 2015 and 2014, respectively. The 2014 amounts were partially offset by the rent income of approximately $6,000 and $42,000, respectively, for sublet space. We did not sublet any space during the nine months ended September 30, 2015.

As of September 30, 2015, future minimum rental payments are as follows:

Years Ending December 31,
	2015 (3 months)	$	121,698
	2016		493,790
	2017		507,087
	2018		388,976
	Minimum lease payments	$	1,511,551

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

	Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
	Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
	Level 3	unobservable inputs for the asset or liability.

At September 30, 2015 and December 31, 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.

The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test.

Revenue Recognition

Over-the-Counter Products

Prescription Products

Research and Development Expenses

Segment Reporting

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References+ Details

INVENTORY (Tables)

9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following:

	September 30, 2015		December 31, 2014
Finished product	$	787,232	$	874,294
Raw material		82,827		155,341
Deferred costs		—		152,478
TOTAL INVENTORY	$	870,059	$	1,182,113

FIXED ASSETS, NET (Tables)

9 Months Ended

Sep. 30, 2015

Property, Plant and Equipment [Abstract]

Schedule of fixed assets

Fixed assets, net consist of the following:

	September 30, 2015			December 31, 2014
Equipment	$	132,150		$	132,150
Furniture and fixtures		69,454			53,895
		201,604			186,045
Accumulated depreciation		(144,856	)		(122,752	)
TOTAL FIXED ASSETS, NET	$	56,748		$	63,293

INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2015 and December 31, 2014:

	September 30, 2015
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:
OPERA^®software patent	$	31,951	$	(3,994	)	$	27,957		14
Development costs of
corporate website		91,743		(91,743	)		—		n/a
Approved hormone
therapy drug
candidate patents		605,502		(40,199	)		565,303		17.25
Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents
(pending)		585,241		—			585,241		n/a
Multiple trademarks for
vitamins/supplements		145,783		—			145,783		indefinite
Total	$	1,460,220	$	(135,936	)	$	1,324,284

	December 31, 2014
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:
OPERA^®software patent	$	31,951	$	(2,496	)	$	29,455		14.75
Development costs of
corporate website		91,743		(91,743	)		—		n/a
Approved hormone
therapy drug
candidate patents		439,184		(19,401	)		419,783		18
Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents
(pending)		675,982		—			675,982		n/a
Multiple trademarks for
vitamins/supplements		103,368		—			103,368		indefinite
Total	$	1,342,228	$	(113,640	)	$	1,228,588

Schedule of estimated amortization expense

Estimated amortization expense for the next five years is as follows:

Year Ending December 31,		Estimated Amortization
	2015 (3 months)	$	8,692
	2016	$	34,768
	2017	$	34,768
	2018	$	34,768
	2019	$	34,768

NET LOSS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2015

Net Loss Per Share Tables

Schedule of potentially dilutive securities

	As of September 30,
	2015		2014
Stock options		17,414,242		16,851,943
Warrants		12,722,431		13,927,916
		30,136,673		30,779,859

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2015

Stockholders' Equity Note [Abstract]

Schedule of assumptions used in the Black-Scholes Model of stock options

The assumptions used in the Black-Scholes Model during the nine months ended September 30, 2015 and 2014 are set forth in the table below.

	Nine Months Ended September 30,
	2015			2014
Risk-free interest rate		1.47-1.54	%		1.68-1.77	%
Volatility		58.77-62.94	%		69.15-70.93	%
Term (in years)		5.27-6.25			5-6.25
Dividend yield		0.00	%		0.00	%

Schedule of option activity

A summary of activity under the 2009 and 2012 Plans and related information follows:

	Number of Shares Underlying Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2014		16,792,443		$	1.88		6.92	$	43,996,311
Granted		1,231,000		$	6.38
Exercised		(472,867	)	$	1.25
Expired/Forfeited		(136,334	)	$	3.01
Balance at September 30, 2015		17,414,242		$	2.21		6.09	$	64,265,785
Vested and Exercisable at September 30, 2015		13,848,923		$	1.59		5.49	$	59,095,453

COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2015

Commitments And Contingencies Tables

Schedule of future minimum rental payments

As of September 30, 2015, future minimum rental payments are as follows:

Years Ending December 31,
	2015 (3 months)	$	121,698
	2016		493,790
	2017		507,087
	2018		388,976
	Minimum lease payments	$	1,511,551

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Advance payments for future research and development activities	$ 948,499	$ 1,175,082
Accrued Expense	1,213,874
Other assets current	755,152
Long term prepaid expense	$ 193,347	$ 463,720

INVENTORY (Details) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Inventory
Finished product	$ 787,232	$ 874,294
Raw material	82,827	155,341
Deferred costs		152,478
TOTAL INVENTORY	$ 870,059	$ 1,182,113

OTHER CURRENT ASSETS (Details) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Other Current Assets
Prepaid insurance	$ 870,949	$ 394,878
Prepaid research and development costs	381,813	299,498
Prepaid consulting	373,339	411,864
Other receivables-related party (Note 13)	249,981	249,981
Other prepaid costs	219,086	181,186
Prepaid vendor deposits	25,637
TOTAL OTHER CURRENT ASSETS	$ 2,120,805	$ 1,537,407

- Definition

The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).

+ References+ Details

- Definition

Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References+ Details

FIXED ASSETS, NET (Details) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Fixed assets, gross	$ 201,604	$ 186,045
Accumulated depreciation	(144,856)	(122,752)
TOTAL FIXED ASSETS	56,748	63,293
Equipment [Member]
Fixed assets, gross	132,150	132,150
Furniture and Fixtures [Member]
Fixed assets, gross	$ 69,454	$ 53,895

PREPAID EXPENSE (Details) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Prepaid Expense and Other Assets [Abstract]
Prepaid manufacturing costs	$ 978,704	$ 963,543
Prepaid research and development costs	193,347	463,720
TOTAL PREPAID EXPENSE	$ 1,172,051	$ 1,427,263

INTANGIBLE ASSETS (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
INTANGIBLE ASSETS (Details Narrative) (USD $)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 8,692	$ 5,625	$ 22,296	$ 17,196
Number of patents	13		13

INTANGIBLE ASSETS (Details ) (USD $)	9 Months Ended	12 Months Ended
INTANGIBLE ASSETS (Details ) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets
Accumulated Amortization	$ (135,936)	$ (113,640)
Indefinite-Lived Intangible Assets
Gross Carrying Amount	1,460,220	1,342,228
Net Amount	1,324,284	1,228,588
Hormone therapy drug candidate patents - Pending [Member]
Indefinite-Lived Intangible Assets
Gross Carrying Amount	585,241	675,982
Net Amount	585,241	675,982
Multiple trademarks for vitamins/supplements [Member]
Indefinite-Lived Intangible Assets
Gross Carrying Amount	145,783	103,368
Net Amount	145,783	103,368
OPERA software patent [Member]
Finite-Lived Intangible Assets
Gross Carrying Amount	31,951	31,951
Accumulated Amortization	(3,994)	(2,496)
Net Amount	27,957	29,455
Weighted Average Amortization Period	14 years	14 years 9 months
Development costs for corporate website [Member]
Finite-Lived Intangible Assets
Gross Carrying Amount	91,743	91,743
Accumulated Amortization	(91,743)	(91,743)
Net Amount
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets
Gross Carrying Amount	605,502	439,184
Accumulated Amortization	(40,199)	(19,401)
Net Amount	$ 565,303	$ 419,783
Weighted Average Amortization Period		18 years
Non-Amortizing Intangible Assets [Member]
Finite-Lived Intangible Assets
Weighted Average Amortization Period	17 years 2 months 30 days

INTANGIBLE ASSETS (Details 1) (USD $)	Sep. 30, 2015
Estimated amortization expense for the year:
2015 (3 months)	$ 8,692
2016	34,768
2017	34,768
2018	34,768
2019	$ 34,768

OTHER CURRENT LIABILITIES (Details) (USD $)

Sep. 30, 2015

Dec. 31, 2014

Other Liabilities Disclosure [Abstract]

Accrued clinical trial costs

$ 3,528,061

$ 1,706,542

Accrued payroll, bonuses and commission costs

930,913

814,205

Accrued legal and accounting expense

615,946

276,470

Accrued compensated absences

490,170

442,430

Other accrued expenses

388,268

^[1]

185,965

^[1]

Allowance for coupons and returns

208,361

90,446

Allowance for wholesale distributor fees

96,440

160,503

Accrued rent

86,998

91,368

Accrued royalties

41,620

72,710

TOTAL OTHER CURRENT LIABILITIES

$ 6,386,777

$ 3,840,639

[1]	In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2015 and December 31, 2014.

NET LOSS PER SHARE (Details)	9 Months Ended
NET LOSS PER SHARE (Details)	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from earnings per share calculation	30,136,673	30,779,859
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from earnings per share calculation	17,414,242	16,851,943
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from earnings per share calculation	12,722,431	13,927,916

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	3 Months Ended	9 Months Ended			9 Months Ended		0 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Sep. 30, 2014 Options exercised 1 [Member]	Sep. 30, 2014 Options exercised 2 [Member]	Jul. 09, 2015 Stifel Underwriters [Member]	Jul. 15, 2015 Stifel Underwriters [Member]	Feb. 10, 2015 Cowen and Company, LLC (Underwriters) [Member]	Feb. 17, 2015 Cowen and Company, LLC (Underwriters) [Member]	Jul. 29, 2014 Goldman Sachs Underwriters [Member]	Aug. 04, 2014 Goldman Sachs Underwriters [Member]
Preferred stock, shares authorized	10,000,000	10,000,000		10,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001		$ 0.001
Common stock, shares authorized	350,000,000	350,000,000		250,000,000
Common stock, shares issued	177,787,927	177,787,927		156,097,019		113,837
Common stock, shares outstanding	177,787,927	177,787,927		156,097,019
Number of shares issued during the period							3,846,154	4,423,077	13,580,246	15,617,282	8,565,310	9,850,106
Share price (in dollars per share)							$ 7.80		$ 4.05		$ 4.67
Number of shares issued during the period,value							$ 3,200,000		$ 59,100,000		$ 42,800,000
Number of common stock issued during period for stock options exercised	95,000	472,867	793,800		674,800	119,607	576,923		2,037,036		1,284,796
Value of common stock issued during period for stock options exercised	$ 98,478	$ 589,867			$ 315,546
Share based compensation options grants in period		1,231,000	50,000

STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	9 Months Ended		1 Months Ended	9 Months Ended	0 Months Ended			3 Months Ended		9 Months Ended			3 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	Sep. 30, 2015	Sep. 30, 2014	May 31, 2013 Sancilio and Company Warrants [Member]	Sep. 30, 2015 Sancilio and Company Warrants [Member]	Jun. 30, 2013 Sancilio &amp; Company Warrants 1st Installments [Member]	May 11, 2013 Sancilio &amp; Company Warrants 1st Installments [Member]	Jun. 30, 2013 Sancilio and Company Warrants 2nd Installments [Member]	Sep. 30, 2015 Sancilio and Company Warrants 2nd Installments [Member]	Sep. 30, 2014 Sancilio and Company Warrants 2nd Installments [Member]	Sep. 30, 2015 Sancilio and Company Warrants 2nd Installments [Member]	Sep. 30, 2014 Sancilio and Company Warrants 2nd Installments [Member]	Sep. 30, 2015 Sancilio and Company Warrants 3rd Installments [Member]	Sep. 30, 2015 Outside Consultant Warrants [Member]	Sep. 30, 2015 Outside Consultant Warrants [Member]	Jan. 31, 2013 Multiple Advance Revolving Credit Note (Plato Warrant) [Member]	Sep. 30, 2015 Multiple Advance Revolving Credit Note (Plato Warrant) [Member]	Sep. 30, 2014 Multiple Advance Revolving Credit Note (Plato Warrant) [Member]
Warrants:
Warrants outstanding	$ 12,772,431
Weighted-average contractual remaining life				1 year 9 months										1 year 11 months 1 day
Exercise price of warrants (in dollars per share)	$ 1.93		$ 2.01										$ 6.35	$ 6.35	$ 3.20
Unamortized costs of warrants				567,000
Number of shares purchased			850,000			283,333	283,333					283,334			1,250,000
Expiration date of warrants														Apr. 06, 2020	Jan. 31, 2019
Vesting date of warrants						Jun. 30, 2013									Oct. 31, 2013
Fair value of warrants					405,066		462,196								1,711,956
Expected term					5 years		5 years								6 years
Volatility rate					45.89%		45.84%								44.29%
Risk free rate					1.12%		1.41%								0.88%
Dividend yield					0.00%		0.00%								0.00%
Amortization deferred financing costs																0	260,027
Number of shares purchased forfeit			833,000
Valuation method of warrants					Black-Scholes Model
Non-cash compensation recognised					405,066			38,517	38,517	115,551	115,551		42,266	86,008
Other current assets	$ 755,152							$ 115,543		$ 115,543
Options Granted	1,231,000	50,000												50,000

STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	3 Months Ended		9 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Option exercise prices (in dollars per shares)	$ 2.21		$ 2.21		$ 1.88
Share-based compensation expense	$ 1,626,862	$ 1,047,493	$ 4,328,964	$ 3,341,604
Total unrecognized estimated compensation expense	5,593,000		5,593,000
Recognized weighted-average period			2 years 3 months 19 days
Options granted			1,231,000	50,000
Stock issued for excercised warrants, shares				365,583
Stock issued for excercised warrants, value				181,000
Warrant Exercised 1 [Member]
Stock issued for excercised warrants, shares			945,485
Stock issued for excercised warrants, value			$ 366,000
Warrant Exercised 2 [Member]
Number of shares issued	232,197		232,197
Stock issued for excercised warrants, shares	310,000		310,000
Minimum [Member]
Option exercise prices (in dollars per shares)	$ 0.10		$ 0.10
Maximum [Member]
Option exercise prices (in dollars per shares)	$ 7.72		$ 7.72
2009 Long Term Incentive Compensation Plan [Member]
Description of plan			To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards.
Number of shares authorized for issuance					25,000,000
Number of shares issued			15,445,768
Options granted			1,231,000
2012 Stock Incentive Plan [Member]
Description of plan			Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.
Number of shares authorized for issuance					10,000,000
Number of shares issued			1,968,474

STOCKHOLDERS' EQUITY (Details) (Stock Options [Member])	9 Months Ended
STOCKHOLDERS' EQUITY (Details) (Stock Options [Member])	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.47%	1.68%
Expected Volatility	58.77%	69.15%
Expected term	5 years 3 months 8 days	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.54%	1.77%
Expected Volatility	62.94%	70.93%
Expected term	6 years 2 months 30 days	6 years 2 months 30 days

STOCKHOLDERS' EQUITY (Details 1) (USD $)	3 Months Ended	9 Months Ended
STOCKHOLDERS' EQUITY (Details 1) (USD $)	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Number Options
Options outstanding, beginning		16,792,443
Options Granted		1,231,000	50,000
Options Exercised	(95,000)	(472,867)	(793,800)
Options Cancelled		(136,334)
Options outstanding, ending	17,414,242	17,414,242
Vested and exercisable	13,848,923	13,848,923
Weighted Average Exercise Price
Options outstanding, beginning		$ 1.88
Granted		$ 6.38
Exercised		$ 1.25
Cancelled		$ 3.01
Options outstanding, ending	$ 2.21	$ 2.21
Vested and exercisable	$ 1.59	$ 1.59
Weighted Average Remaining Contractual Life
Options outstanding, beginning		6 years 11 months 1 day
Options outstanding, ending		6 years 1 month 2 days
Vested and exercisable		5 years 5 months 27 days
Aggregate Intrinsic Value
Options outstanding, beginning		$ 43,996,311
Options outstanding, ending	64,265,785	64,265,785
Vested and exercisable	$ 59,095,453	$ 59,095,453

RELATED PARTIES (Details Narrative) (Pernix Therapeutics LLC [Member], USD $)	Sep. 30, 2015	Dec. 31, 2014
Pernix Therapeutics LLC [Member]
Receivables- legal fee reimbursement	$ 250,000	$ 250,000
Payable - related party	$ 46,000	$ 46,000

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References+ Details

BUSINESS CONCENTRATIONS (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
BUSINESS CONCENTRATIONS (Details Narrative) (USD $)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Concentration Risk [Line Items]
Revenues	$ 5,190,175	$ 4,186,261	$ 14,513,158	$ 10,768,572
Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk			54.00%	77.00%
Customer Concentration Risk [Member] \| Sales Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk			90.00%	95.00%
Customer Concentration Risk [Member] \| Sales Revenue [Member] \| Minimum [Member]
Concentration Risk [Line Items]
Concentration Risk			10.00%	10.00%
Customer A [Member] \| Sales Revenue [Member]
Concentration Risk [Line Items]
Revenues			6,930,000	3,930,000
Customer B [Member] \| Sales Revenue [Member]
Concentration Risk [Line Items]
Revenues			3,005,000	1,846,000
Customer C [Member] \| Sales Revenue [Member]
Concentration Risk [Line Items]
Revenues				1,590,000
Customer D [Member] \| Sales Revenue [Member]
Concentration Risk [Line Items]
Revenues				$ 1,555,000

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable operating lease term			63 months
Rental Expense	$ 119,000	$ 90,000	$ 328,000	$ 271,000
Rental income		$ 6,000		$ 42,000

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Sep. 30, 2015
Future minimum rental payments, year ending December 31,
2015 (3 months)	$ 121,698
2016	493,790
2017	507,087
2018	388,976
Minimum lease payments	$ 1,511,551

FIXED ASSETS, NET (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
FIXED ASSETS, NET (Details Narrative) (USD $)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Property, Plant and Equipment [Abstract]
Depreciation Expense	$ 7,856	$ 7,122	$ 22,104	$ 22,713